JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2020, Vol. 40 ›› Issue (12): 1665-1671.doi: 10.3969/j.issn.1674-8115.2020.12.018

• Review • Previous Articles     Next Articles

Clinical application of receptor tyrosine kinase inhibitors to acute myeloid leukemia

DONG Xin-yi1, FAN Qiu-yue1, QIU Shu-han1, ZHOU Jia-yao1, LU Ying2   

  1. 1.Department of Clinical Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; 2.Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2020-12-28 Published:2021-02-02
  • Supported by:
    National Natural Science Foundation of China(81770146, 81970131); The 13th Undergraduate Training Programs for Innovation of Shanghai Jiao Tong University School of Medicine (1319083).

Abstract: Receptor tyrosine kinases (RTKs) control the basic activities of cells including proliferation, cell cycle, apoptosis, metabolism and so on. Accordingly, abnormal activation caused by mutations of RTKs plays an important part in the formation and development of tumor. For the past few years, the receptor tyrosine kinase inhibitors (rTKI) developed for RTKs have progressed rapidly and achieved good results in clinical treatment in various tumor types, such as chronic myelogenous leukemia, non-small cell lung cancer, breast cancer and so on. As for acute myeloid leukemia (AML), approval and clinical application of inhibitors against Fms-like tyrosine kinase 3 (FLT3) significantly improve prognosis in patients with FLT3 mutations, which is vital for the treatment of AML. The clinical application of rTKI to AML is summarized in this review, providing a reference for the treatment of AML.

Key words: acute myeloid leukemia (AML), receptor tyrosine kinases (RTKs), receptor tyrosine kinase inhibitors (rTKI)

CLC Number: